healthpharma
Zealand Pharma (CPH: ZEAL) rallied more than 20% this morning after reporting positive results from an early stage trial of its new weight loss treatment. The biotech firm is now trading at an all-time high. Why is it significant for Zealand Pharma stock?Petrelintide – a long-acting amylin analog of Zealand Pharma showed significant efficacy in a 16-week trial, as per its press release on Friday. Participants receiving high doses successfully lowered their body weight by 8.6% versus only 1.7% observed in the placebo group. Only one participant out of a total of 48 had to withdraw from the stud...
Invezz
Sarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price shoot up by 36% in after-hours trading last night. But why? Ground-breaking medical breakthroughToward the end of the trading day yesterday, Sarepta announced that it had obtained approval from the U.S. Food and Drug Administration (FDA) for a treatment targeting a rare genetic disease called Duchenne muscular dystrophy (DMD). Sarepta’s DMD treatment, named ELEVIDYS (delandistrogene moxeparvovec-rokl), was given full FDA appr...
Invezz
Sarepta Therapeutics Inc (NASDAQ: SRPT) rallied a whopping 40% in extended hours today following a key announcement from the U.S. Food and Drug Administration regarding Elevidys. Elevidys is the company’s treatment for Duchenne muscular dystrophy. Why is it significant for Sarepta Therapeutics stock?The FDA granted accelerated approval for a label expansion of “delandistrogene moxeparvovec” to include non-ambulatory patients on Thursday. The decision is significant for individuals with DMD who have lost the ability to walk. Jerry Mendell – the co-inventor of Elevidys said in a press release%2C...
Invezz
Pfizer (NYSE: PFE) stock price has crashed hard in the past few years as demand for Covid-19 vaccines faded globally. It was trading at $28 on Monday, down from the pandemic high of $55.56. It has also underperformed the likes of Eli Lilly, Johnson & Johnson, and Amgen. Pfizer’s history of acquisitionsPfizer’s crash has brought focus on the company’s history of growth through acquisitions. In 2023, the company acquired Seagen in a $43 billion deal, a move that gave it access to cancer treatments. Seagen had over $2 billion in annual revenue in 2023 and has 113 drugs in its pipeline. While Seag...
Invezz
The Mustang Bio stock price closed on a high yesterday, trading at $0.75. The pharmaceutical company has gone vertical in the past 24 hours, climbing 476.9% to go from $0.13 to $0.75 in a single day. But why? Potential cancer breakthroughYesterday, Mustang Bio announced via press release that it had had promising results from clinical trials relating to an experimental treatment developed by Mustang Bio for Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer. The trial, which contained just 10 patients, showed a marked improvement over more traditional existing treatments for the...
Invezz
AstraZeneca, the largest pharmaceutical group in Britain, announced that the U.S. Food and Drug Administration (FDA) has approved its lung cancer drug, Imfinzi, for use alongside other chemotherapy treatments. The approval is specifically for Imfinzi in combination with carboplatin and paclitaxel, followed by Imfinzi monotherapy. This regimen is intended for adults suffering from primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). Significant trial resultsThe approval follows a clinical trial that demonstrated Imfinzi’s efficacy in reducing the risk of di...
Invezz
Longeveron Inc (NASDAQ: LGVN) rallied another 50% on Thursday as investors continued to celebrate the positive update of its Lomecel-B study. Why is it significant for Longeveron stock?The biotech firm reported encouraging investigator data from the said Phase 2 trial on Tuesday. Lomecel-B is its candidate treatment for hypoplastic left heart syndrome (HLHS). Note that the ELPIS II study is still ongoing. Ram Kumar – the principal investigator of that clinical trial said in a press release today: Lomecel-B clinical data is highly encouraging and suggests it has the potential to be a new, addit...
Invezz
Rentokil Initial (LON: RTO) share price went parabolic on Wednesday as the company entered a new phase as Elliot Management became one of its biggest investors. The stock soared by more than 13% and reached its highest swing since March 15th. It has soared by more than 18% from its lowest point this year. Elliot Management to push changesRentokil Initial, one of the biggest players in the pest control, is now in the spotlight after Elliot Management took an over £400 million stake in the firm. This action happened at a time when the stock has languished as the company went through a major slow...
Invezz
Alzheimer’s could eventually be a “very big category” for Eli Lilly & Co (NYSE: LLY), says Dr Scott Gottlieb. He’s the former commission of the U.S. Food & Drug Administration. FDA advisors vote in favour of Lilly’s donanemabLilly received backing for its Alzheimer’s drug from a panel of advisors to the FDA on Monday. It’s an “important development for patients” because donanemab is more efficacious and required just one dose per month versus two for a similar drug from Biogen, Dr Gottlieb added in an interview with CNBC today. Still, Biogen has called its Alzheimer’s drug that targets tau pro...
Invezz
Artificial intelligence could be a huge benefit for the health care space, says Fred Hassan. He’s chairman of the Caret Group. What parts of health care could benefit from AI?Hassan expects AI to help boost productivity across the board in the health sector – be it drug discovery, clinical trials, or patient management. Infectious diseases and oncology in particular will benefit from artificial intelligence in the near term, he told CNBC in a recent interview. Chairman Hassan forecasts AI to be a positive for GLP-1s (weight-loss drugs) as well. Last week, Sanofi partnered with OpenAI to deploy...
Invezz
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら